Turner Christopher T, Hasanzadeh Kafshgari Morteza, Melville Elizabeth, Delalat Bahman, Harding Francis, Mäkilä Ermei, Salonen Jarno J, Cowin Allison J, Voelcker Nicolas H
Regenerative Medicine, Future Industries Institute, University of South Australia, Adelaide, South Australia 5001, Australia.
ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Future Industries Institute, University of South Australia, Adelaide, South Australia 5001, Australia.
ACS Biomater Sci Eng. 2016 Dec 12;2(12):2339-2346. doi: 10.1021/acsbiomaterials.6b00550. Epub 2016 Nov 9.
Flightless I (Flii), a cytoskeletal actin remodelling protein, is elevated in wounds and is a negative regulator of wound healing. Gene silencing using small interfering RNA (siRNA) is an attractive approach to antagonize Flii, and therefore holds significant promise as a therapeutic intervention. The development of siRNA therapeutics has been limited by an inability of the siRNA to cross the cell surface plasma membrane of target cells and also by their degradation due to endogenous nuclease action. To overcome these limitations, suitable delivery vehicles are required. Porous silicon (pSi) is a biodegradable and high surface area material commonly used for drug delivery applications. Here we investigated the use of pSi nanoparticles (pSiNPs) for the controlled release of Flii siRNA to wounds. Thermally hydrocarbonized pSiNPs (THCpSiNPs) were loaded with Flii siRNA and then coated with a biocompatible chitosan layer. Loading regimens in the order of 50 μg of Flii siRNA per mg of pSi were achieved. The release rate of Flii siRNA was sustained over 35 h. With addition to keratinocytes , reduced Flii gene expression in conjunction with lowered Flii protein was observed, in concert with increased cell migration and proliferation. A significant improvement in the healing of acute excisional wounds compared to controls was observed from day 5 onward when Flii siRNA-THCpSiNPs were intradermally injected. THCpSiNPs therefore are an effective vehicle for delivering siRNA, and nanoparticle-based siRNA delivery represents a promising therapeutic approach to improve wound healing.
肌动蛋白解聚因子(Flii)是一种细胞骨架肌动蛋白重塑蛋白,在伤口中表达上调,是伤口愈合的负调节因子。使用小干扰RNA(siRNA)进行基因沉默是拮抗Flii的一种有吸引力的方法,因此作为一种治疗干预手段具有重要前景。siRNA疗法的发展受到siRNA无法穿过靶细胞的细胞表面质膜以及其因内源性核酸酶作用而降解的限制。为克服这些限制,需要合适的递送载体。多孔硅(pSi)是一种可生物降解且具有高表面积的材料,常用于药物递送应用。在此,我们研究了使用pSi纳米颗粒(pSiNPs)将Flii siRNA控释至伤口。将热碳化pSiNPs(THCpSiNPs)装载Flii siRNA,然后用生物相容性壳聚糖层进行包被。实现了每毫克pSi装载约50μg Flii siRNA的装载方案。Flii siRNA的释放速率持续了35小时。除角质形成细胞外,观察到Flii基因表达降低以及Flii蛋白水平降低,同时细胞迁移和增殖增加。当皮内注射Flii siRNA-THCpSiNPs时,从第5天起观察到与对照组相比急性切除伤口的愈合有显著改善。因此,THCpSiNPs是递送siRNA的有效载体,基于纳米颗粒的siRNA递送代表了一种有前景的改善伤口愈合的治疗方法。